New online melanoma risk calculators critical to saving lives
28 August 2020
Clinicians and their patients now have access to a series of online calculators which will assist in prevention, early detection and optimum treatment of melanoma, ultimately saving lives.
Developed by researchers at Melanoma Institute Australia and based on published risk prediction models, the three web-based calculators are housed on a new Melanoma Risk website launched today.
They predict a person’s risk of developing their first melanoma; their risk of developing a second or subsequent primary melanoma; and their risk of a primary melanoma having spread to nearby lymph nodes.
MIA Co-Medical Directors, Professor Richard Scolyer and Professor Georgina Long AO, said the risk calculators were the latest in the growing arsenal of early detection tools and ground-breaking treatments which they believed would culminate in achieving zero deaths from melanoma this decade.
‘Awareness, prevention, early detection and optimum treatment are key when it comes to tackling melanoma and saving lives from this disease,’ said Professor Richard Scolyer.
‘The online risk calculators are designed to inform discussions between clinicians and patients; two promote prevention and tailored skin surveillance programs for early detection and the third facilitates specialised treatment plans according to the specific patient’s risk,’ he said.
‘The development of these wonderful online tools is testament to the great work of many of our researchers and clinicians at MIA and will move us closer to reaching zero deaths from melanoma,’ added Professor Georgina Long AO.
Currently, Australia has one of the highest melanoma rates in the world with one person diagnosed every 30 minutes and one person dying every five hours from the disease.
The launch of the calculators comes amidst concerns the COVID-19 pandemic may have caused Australians to delay seeking checkups for melanoma and other cancers where early detection is vital for optimum outcomes.
Two of the calculators use patient information such as age, skin type, family history and sun exposure history to calculate individual lifetime risk of a person developing either their initial primary melanoma or a subsequent one. This information then guides discussions between the patient and the clinician about appropriate sun protection behaviours as well as the optimum schedule of skin checks to ensure early detection.
The third calculator predicts risk of disease having spread from a primary melanoma to nearby lymph nodes, and potentially metastasising to other vital organs. It takes into account additional clinical information about the primary melanoma as well as a patient’s age.
This calculator enables those deemed to be at low risk of disease spread to safely forgo surgery for a sentinel node biopsy. Conversely, it also detects patients at higher risk of disease spread, increasing potential for earlier identification of lymph node spread and activation of optimum treatment.
‘This calculator predicting risk of disease spread is particularly of benefit to older patients who are less likely to have melanoma spread to their lymph nodes, but who are at increased risk of complications that can come from additional surgery and general anaesthesia,’ added Professor Long AO.
The three web-based calculators can be accessed at www.melanomarisk.org.au
Updated guidelines defining appropriate excision margins have been published thanks to research from MIA.
Joanne and her trusty companion Frankie spend their days spreading a message of hope in hospitals, nursing homes, even prisons. It is a long way from her darkest hour facing palliative care. This is her story of hope.
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.